

CEFACLOR

Trade Name	Ranbaxy-Cefaclor Douglas Pharmaceuticals Ltd.
Class	Cephalosporin antibiotic (2 nd Generation)
Mechanism of Action	Inhibits bacterial cell wall synthesis
Indications	Indication 1: Treatment of infections caused by susceptible organisms including S aureus, E. coli, H. influenza Indication 2: Treatment of urinary tract infections Indication 3: Prophylaxis of urinary tract infections
Contraindications	Known history of allergy to cefaclor or other cephalosporins.
Supplied As	Powder for oral suspension 125 mg /5 mL Forms a red strawberry flavoured solution when reconstituted
Dilution	Reconstitute with sterile water as per manufacturer's instructions on the label of the bottle. ie: 125mg/5mL - add 70mL water to make up to 100mL final soln. Shake well before use.
Dosage	Indication 1 and 2: 10 mg/kg/dose Indication 3: 10mg/kg/dose
Guardrail	N/A
Interval	Indication 1 and 2: 8 hourly Indication 3: Once at night
Administration	Oral
Compatible With	N/A
Incompatible With	N/A
Interactions	Possibility of increased risk of renal toxicity if given in combination with furosemide or aminoglycosides eg gentamicin. Clearance of cefaclor is reduced in the presence of probenecid. Cefaclor may interfere with the results of some lab tests including inducing positive coombes tests, false positive urinary glucose Clinitest®) and urinary creatinine (Jaffe test®).
Monitoring	Nil specific
Stability	Discard any remaining solution 14 days after reconstitution.
Storage	Store dry powder at room temperature. Reconstituted solution should be stored in the fridge at 2- 8 °C

Adverse Reactions	Diarrhoea, eosinophilia, haemolytic anaemia, interstitial nephritis, elevated transaminases, rash, cholestatic jaundice, vomiting, nausea, itch, Stevens Johnson syndrome, serum sickness.
Metabolism	Cefaclor is predominantly excreted unchanged by the kidneys.
Comments	Cefaclor is not currently registered for use in neonates less than 1 month old
References	<ol style="list-style-type: none"> 1. www.nzf.org.nz 2. Taketomo et al Paediatric Drug Information Handbook 2010. 3. www.medsafe.govt.nz 4. http://www.adhb.govt.nz/newborn/drugprotocols/CefaclorPharmacology.htm
Updated By	A Lynn, B Robertshawe June 2014 A Lynn, M Wallenstein, B Robertshawe (content check) September 2020